A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo in Previously Untreated, Stage IV, Metastatic Non-small Cell Lung Cancer Subjects Whose Tumors Are PD-L1 Positive (TPS ≥ 50%) (KEYNOTE-598)
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 27 Nov 2017
At a glance
- Drugs Ipilimumab (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms KEYNOTE-598
- Sponsors Merck Sharp & Dohme
- 21 Nov 2017 Planned primary completion date changed from 18 Apr 2022 to 28 Feb 2023.
- 21 Nov 2017 Planned initiation date changed from 24 Nov 2017 to 4 Dec 2017.
- 11 Oct 2017 New trial record